TreatmentStudiesBenefitPer life saved$0$2.4M
TreatmentStudiesBenefitPer life saved$0$2.4M
Cost estimates are the treatment cost times the median NNT (number needed to treat) from studies reporting mortality results with calculable NNT. Mortality estimates are the results of meta-analysis. Costs are in $US and based on estimated costs for widespread distribution by governments. Results reflect conditions in trials to date, these depend on the population treated, treatment delay, and treatment regimen, e.g., vitamin C results are dominated by very late treatment studies with high control mortality. Dexamethasone shows benefit only for severe/critical patients, and higher risk is seen for earlier treatment.
0.4% of treatments show efficacy. This table shows
the cost per life saved for effective treatments - treatment cost times the median NNT
(number needed to treat) from studies reporting mortality results with calculable NNT.
Costs are shown in $US and based on estimated costs for widespread
distribution by governments. Results reflect conditions in trials to date, these depend on
the population treated, treatment delay, and treatment regimen. For example, vitamin C
results are dominated by very late treatment studies with high control mortality.
Dexamethasone shows benefit only for severe/critical patients, and higher risk is shown
for earlier treatment. Click the treatment name to see all studies, where the name of each
study can be clicked on for the source papers. No treatment is 100% effective. Protocols
typically combine multiple treatments which may be complementary and synergistic.
Treatment efficacy may vary by variant, especially for monoclonal antibodies. Only
medications with ≥3 results are shown. Cost per life saved may increase for variants with
lower virulence. All treatments have potential side effects. Not all treatments are shown.
129 of the treatments we cover show increased risk - we note commonly recommended treatments in this group. All practical, effective, and safe means
should be used based on risk/benefit analysis.